Clinical Trials | December 30, 2025
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
The study met its primary endpoint with flying colors
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
Harbour BioMed brings advanced antibody discovery platforms to the table
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
Subscribe To Our Newsletter & Stay Updated
